CagriSema vs Amycretin
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Semaglutide + Cagrilintide
CagriSema is a once-weekly injectable that pairs two drugs in one shot: semaglutide (a GLP-1 receptor agonist, the molecule behind Ozempic and Wegovy) and cagrilintide (a long-acting amylin analog). It is being developed by Novo Nordisk for obesity and type 2 diabetes, and in 2025 it cleared its phase 3 REDEFINE trials. It is not yet approved by the FDA, though regulatory filings are underway.
Also: Zenagamtide, NNC0487-0111
Amycretin is Novo Nordisk's single-molecule agonist of both the GLP-1 and amylin receptors, developed as a once-weekly injection and a once-daily pill. Early trials produced some of the biggest weight-loss numbers seen with any obesity drug so far, and the injectable version entered phase 3 (the AMAZE program) in 2026. It is not approved anywhere, and everything known about it comes from company-run trials of up to 36 weeks.
Key Comparison Insights
- Both peptides belong to the Weight Loss category, suggesting similar primary applications.
Detailed Comparison
| Attribute | CagriSema | Amycretin |
|---|---|---|
| Category | Weight Loss | Weight Loss |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | The combination works on two different appetite systems at once. Semaglutide mimics GLP-1, a gut hormone that boosts insulin after meals, slows stomach emptying, and signals fullness to the brain. Cagrilintide is a synthetic version of amylin, a hormone co-secreted with insulin from the pancreas, which reduces food intake and reinforces satiety through separate brain circuits in the hindbrain and hypothalamus. The idea, still being characterized, is that hitting GLP-1 and amylin pathways together produces more appetite suppression than either alone. Both components are engineered for slow release so a single weekly dose maintains steady drug levels. | Amycretin hits two appetite systems at once. The GLP-1 side slows stomach emptying, boosts insulin release after meals, and dampens appetite in the brain, the same biology behind semaglutide. The amylin side mimics a hormone your pancreas releases alongside insulin, which acts on the brainstem to make you feel full sooner and also curbs glucagon after eating. Novo combined these two signals in one molecule rather than mixing two drugs (which is what its CagriSema combination does). The bet is that the two pathways add together, giving more weight loss than either alone. That idea fits the early data, but it has not yet been tested head-to-head against semaglutide or tirzepatide in a large trial. |
| Common Dosing | Limited community data available See research protocols | Trial doses of 1.25-40 mg once weekly (injection) Once weekly (injection) or once daily (tablet) |
| Administration | Subcutaneous injection weekly | Subcutaneous injection once weekly, or oral tablet once daily (separate formulations) |
| Typical Duration | Long-term use expected | 20-36 weeks in published trials; phase 3 runs longer |
| Best Time to Take | Same day each week, any time of day | Same day each week (injection); trial protocols set timing for the tablet |
Possible Side Effects May vary by individual |
|
|
| Research Summary | This is one of the better-tested experimental obesity drugs because it went straight into large human phase 3 trials rather than living only in animal data. In REDEFINE 1, about 3,400 adults with overweight or obesity but without diabetes were randomized over 68 weeks; CagriSema produced roughly 20.4% average body weight loss versus 14.9% for semaglutide alone, 11.5% for cagrilintide alone, and 3.0% for placebo, with results published in the New England Journal of Medicine in 2025. REDEFINE 2 tested it in adults with type 2 diabetes and also met its endpoints, showing meaningful weight loss and HbA1c improvement compared with placebo. Notably, the headline 20% figure landed below Novo Nordisk's own 25% target, which disappointed investors even though the drug clearly worked. The most common side effects were gastrointestinal: nausea, vomiting, diarrhea, and constipation, consistent with the GLP-1 plus amylin class. CagriSema is not FDA-approved as of mid-2026, so anything sold under that name outside a clinical setting is unregulated. | Two early trials were published in The Lancet in June 2025. In the subcutaneous phase 1b/2a trial (125 adults with overweight or obesity), the estimated weight loss assuming full adherence was 24.3% at 60 mg over 36 weeks and 22.0% at 20 mg over 36 weeks, versus roughly flat weight on placebo, with no plateau by the end of treatment. A separate phase 1 trial of the oral tablet (144 people, 12 weeks) showed up to 13.1% loss at the highest dose. In November 2025 Novo reported a 36-week phase 2 trial in 448 adults with type 2 diabetes: up to 14.5% weight loss with weekly injections (2.6% on placebo), up to 10.1% with the daily pill, and HbA1c drops of up to 1.8 points. Side effects were mostly gastrointestinal, dose-related, and mild to moderate. Novo moved both forms into phase 3; AMAZE 1 (weekly injection at 1.25, 5, 20 or 40 mg versus placebo, about 1,150 people without diabetes) is registered as NCT07339423 with completion expected in 2029. Honest caveats: the headline numbers come from small trials using an efficacy estimand that assumes everyone stayed on drug, and long-term safety is unknown. |
Frequently Asked Questions: CagriSema vs Amycretin
What is the difference between CagriSema and Amycretin?
CagriSema is a weight loss peptide that cagrisema is a once-weekly injectable that pairs two drugs in one shot: semaglutide (a glp-1 receptor agonist, the molecule behind ozempic and wegovy) and cagrilintide (a long-acting amylin analog). it is being developed by novo nordisk for obesity and type 2 diabetes, and in 2025 it cleared its phase 3 redefine trials. it is not yet approved by the fda, though regulatory filings are underway. Amycretin is a weight loss peptide that amycretin is novo nordisk's single-molecule agonist of both the glp-1 and amylin receptors, developed as a once-weekly injection and a once-daily pill. early trials produced some of the biggest weight-loss numbers seen with any obesity drug so far, and the injectable version entered phase 3 (the amaze program) in 2026. it is not approved anywhere, and everything known about it comes from company-run trials of up to 36 weeks. The main differences lie in their mechanisms of action and clinical applications.
Which is better, CagriSema or Amycretin?
Neither is universally "better" - the choice depends on your specific goals. CagriSema is typically used for weight loss purposes, while Amycretin is used for weight loss. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can CagriSema and Amycretin be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using CagriSema and Amycretin together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.